Earnings (Loss) Per Share (Tables)

6 Months Ended

Jun. 30, 2026

Schedule of Earnings (Loss) Per Share, Basic and Diluted

Our basic and diluted earnings (loss) per common share are calculated as follows:


	Three Months Ended				Six Months Ended
in thousands of U.S. dollars and share amounts (except per share amounts)	June 30, 2026		June 30, 2025		June 30, 2026		June 30, 2025
Earnings (Loss):
Net income (loss)	$	53,643	$	7,962	$	80,232	$	(5,298)
Less: Allocation to participating securities	—		1		—		—
Net income (loss) attributable to Sotera Health Company common shareholders	$	53,643	$	7,961	$	80,232	$	(5,298)
Weighted Average Common Shares:
Weighted-average common shares outstanding - basic	285,773		283,933		285,333		283,747
Dilutive effect of potential common shares(a)	2,375		1,823		2,582		—
Weighted-average common shares outstanding - diluted	288,148		285,756		287,915		283,747
Earnings per Common Share:
Net income (loss) per common share attributable to Sotera Health Company common shareholders - basic	$	0.19	$	0.03	$	0.28	$	(0.02)
Net income (loss) per common share attributable to Sotera Health Company common shareholders - diluted	0.19		0.03		0.28		(0.02)

(a)As the Company reported a net loss for the six months ended June 30, 2025, the calculation of diluted weighted average common shares outstanding is not applicable because the effect of including the potential common shares would be anti-dilutive.

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

Diluted earnings per share does not consider the following potential common shares as the effect would be anti-dilutive:


	Three Months Ended		Six Months Ended
in thousands of share amounts	June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
Stock options	4,676	5,566	4,672	8,299
RSUs	375	1,473	254	2,669
PSUs	—	—	—	475
Total anti-dilutive securities	5,051	7,039	4,926	11,443